Neurizon

Showing 2 posts of 2 posts found.

FDA decision on Neurizon’s ALS therapy delayed until October

August 18, 2025
Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …

Neurizon makes appointments to executive team

April 24, 2025
Recruitment, Senior Management Neurizon, Neurology, als, biotech, neurodegenerative diseases

Neurizon Therapeutics, a clinical-stage biotech company focusing on treatments for neurodegenerative diseases, has announced three leadership appointments. These will support …

The Gateway to Local Adoption Series

Latest content